Abstract
The Heart and Estrogen/progestin Replacement Study (HERS) was the first randomized clinical trial of combined hormone therapy and secondary prevention of coronary events. The trial had overall null results but reported an unexpected increased risk for recurrent events in the initial year, followed by a decrease during the final years. To provide additional data on a time trend in risk for recurrent heart disease. A prospective, observational cohort study of secondary prevention of coronary heart disease. Nurses' Health Study. 2489 postmenopausal women with previous myocardial infarction or documented atherosclerosis; 213 cases of recurrent nonfatal myocardial infarction or coronary death were identified from 1976 through 1996. Information on hormone status and on recurrent disease was collected by using biennial questionnaires. Multivariable-adjusted relative risks and 95% CIs were calculated from logistic regression models. A trend of decreasing risk for recurrent major coronary heart disease events with increasing duration of hormone use was observed (P for trend = 0.002). For short-term current users, the multivariate-adjusted relative risk for major coronary heart disease was 1.25 (95% CI, 0.78 to 2.00) compared with never-users. However, after longer-term hormone use, the rate of second events was lower in current users than in never-users (relative risk, 0.38 [CI, 0.22 to 0.66]). No clear differences emerged between users of estrogen alone and users of estrogen combined with progestin. Overall, with up to 20 years of follow-up, the relative risk for a second event among current users of hormone therapy was 0.65 (CI, 0.45 to 0.95) compared with never-users. The risk for recurrent major coronary events seems to increase among short-term hormone users with previous coronary disease but to decrease with longer-term use.
Highlights
MethodsThe Nurses’ Health Study CohortThe Nurses’ Health Study began in 1976, when 121 700 female nurses 30 to 55 years of age completed a mailed questionnaire about postmenopausal hormone use and medical history, including cardiovascular disease and its risk factors
The Heart and Estrogen/progestin ReplacementStudy (HERS) was the first randomized clinical trial of combined hormone therapy and secondary prevention of coronary events
The risk for recurrent major coronary events seems to increase among short-term hormone users with previous coronary disease but to decrease with longer-term use
Summary
The Nurses’ Health Study CohortThe Nurses’ Health Study began in 1976, when 121 700 female nurses 30 to 55 years of age completed a mailed questionnaire about postmenopausal hormone use and medical history, including cardiovascular disease and its risk factors. The total follow-up for the cohort to date exceeds 92% For this analysis, we limited the cohort to postmenopausal women who reported a previous myocardial infarction or documented coronary atherosclerosis (coronary artery bypass graft surgery, percutaneous coronary revascularization, or angiographic evidence of Ն70% occlusion of one or more major coronary arteries). We limited the cohort to postmenopausal women who reported a previous myocardial infarction or documented coronary atherosclerosis (coronary artery bypass graft surgery, percutaneous coronary revascularization, or angiographic evidence of Ն70% occlusion of one or more major coronary arteries) Such women were identified on the baseline questionnaire in 1976; postmenopausal women who reported one of these conditions on a subsequent follow-up questionnaire were added to the sample at that time. These criteria closely parallel those used in HERS [1]; in HERS, women with hysterectomy were excluded, occlusion was defined as at least 50%, and participants ranged in age from 44 to 79 years
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
